• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Syros Pharmaceuticals (NQ: SYRS )

    5.000 -0.170 (-3.29%)
    Streaming Delayed Price Updated: 2:53 PM EDT, Aug 9, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Syros Pharmaceuticals

    < Previous 1 2 3 Next >
    Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Participate in Upcoming Investor Conferences
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Participate in TD Cowen 44th Annual Health Care Conference
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Participate in Upcoming Investor Conferences
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Sidoti Events, LLC's Virtual June Small-Cap Conference
    Via ACCESSWIRE
    Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
    From Syros Pharmaceuticals
    Via Business Wire
    Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
    From Syros Pharmaceuticals
    Via Business Wire
    Syros to Present at JMP Securities 2023 Life Sciences Conference
    From Syros Pharmaceuticals
    Via Business Wire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.